Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?

Lipocine (LPCN) shares soared 5.5% in the last trading session to close at $10. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.2% gain over the past four weeks.Lipocine’s stock price gain can be attributed to increasing investor confidence in recent pipeline developments of its investigational drug LPCN 1154 (oral brexanolone) for the treatment of postpartum depression. The company is evaluating the candidate in phase III stud ...